Table 4.
Effect of Acetazolamide on NREM and REM sleep-disordered breathing events and durations
| Index (events h−1) | Event duration (s) | |||
|---|---|---|---|---|
| Sleep stage | Baseline | Acetazolamide | Baseline | Acetazolamide |
| NREM sleep | ||||
| Overall AHI | 49.6 [35.5–56.6] | 24.0 [12.9–42.3]* | 32.3 ± 2.7 | 37.7 ± 2.8* |
| Central apnoeas | 0 [0–0.2] | 0 [0–0] | 0 [0–15.1] | 0 [0–0] |
| Obstructive apnoeas | 6.0 ± 2.1 | 5.7 ± 2.8 | 23.8 [4.1–39.1] | 26.9 [17.3–43.4] |
| Mixed apnoeas | 0 [0–1.1] | 0 [0–0.2] | 0 [0–28.3] | 0 [0–13.0] |
| Overall hypopnoeas | 33.9 [23.5–50.0] | 17.9 [12.7–29.9]* | 32.1 ± 2.6 | 38.2 ± 2.7* |
| – obstructive | 33.9 [19.9–48.9] | 17.6 [12.7–28.9]* | ||
| – central | 0.3 [0–1.9] | 0.2 [0–0.4] | ||
| REM sleep | ||||
| Overall AHI | 43.2 [31.5–55.7] | 28.0 [18.5–35.0]* | 33.4 ± 3.1 | 38.1 ± 3.7 |
| Central apnoeas | 0 [0–0] | 0 [0–0] | 0 [0–0] | 0 [0–0] |
| Obstructive apnoeas | 9.7 ± 3.6 | 5.2 ± 2.0 | 15.4 [0–29.1] | 15.2 [0–35.3] |
| Mixed apnoeas | 0 [0–1.7] | 0 [0–0] | 0 [0–13.0] | 0 [0–0] |
| Overall hypopnoeas | 30.4 [13.4–47.9] | 23.8 [13.9–28.6] | 35.0 ± 3.3 | 38.9 ± 3.5 |
| – obstructive | 30.4 [10.5–46.6] | 23.8 [13.9–27.8] | ||
| – central | 0 [0–1.9] | 0 [0–0] | ||
Data represent medians [interquartile ranges] or means ± SEM.
*
Significant difference between baseline and acetazolamide